Oral Albuterol Dosing During the Latter Stages of a Resistance Exercise Program
Caruso, J.F., J.L. Hamill, and N. de Garmo. Oral albuterol dosing during the latter stages of a resistance exercise program. J. Strength Cond. Res. 19(1):102-107. 2005.-Subjects performed isoload variable resistance exercise (REX) 3 days per week. After 10 weeks, they received a double-blind albuter...
Gespeichert in:
Veröffentlicht in: | Journal of strength and conditioning research 2005-01, Vol.19 (1), p.102-107 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Caruso, J.F., J.L. Hamill, and N. de Garmo. Oral albuterol dosing during the latter stages of a resistance exercise program. J. Strength Cond. Res. 19(1):102-107. 2005.-Subjects performed isoload variable resistance exercise (REX) 3 days per week. After 10 weeks, they received a double-blind albuterol (n = 11) or placebo (n = 11) capsule assignment with no crossover and continued training. During the first week of capsule administration, dosages were increased from 4 mg to 16 mg daily and then maintained for 14 days. At weeks 0, 10, and 13, we measured upper arm and thigh cross-sectional area, knee and elbow extensor and flexor (KE, KF, EE, EF) strength at 3 angular velocities, and lean body mass. Data after 10 weeks showed insignificant between-group differences. From weeks 10-13, as subjects continued REX training, albuterol evoked higher (p < 0.05) KE-KF strength gains at multiple velocities versus placebo dosing. A higher lean body mass trend also occurred with albuterol from weeks 10-13. Results suggest that albuterol augments REX to provide greater strength gains from hypertrophic factors than an REX-placebo assignment. |
---|---|
ISSN: | 1064-8011 1533-4287 |
DOI: | 10.1519/R-14793.1 |